Danish drugmaker Lundbeck has agreed to spend $2.6 billion acquiring a young biotechnology company with an experimental brain medicine that could become a blockbuster product. The acquisition, ...

H. Lundbeck A/S (Lundbeck) today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland.

H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) ...

Lundbeck just officially welcomed former CEO of Millennium, Deborah Dunsire, as its own chief in September. And as some might expect with a new leader, the central nervous system specialist is now ...

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in ...

June 14 (Reuters) - Danish drugmaker H. Lundbeck said on Sunday its investigational drug asedebart showed encouraging tolerability and results in a small mid-stage study for the treatment of Cushing's ...

VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate Gefion, ...

Lundbeck CEO Deborah Dunsire is stepping down on a high note in the neuroscience company’s history. Dunsire has decided to retire from Lundbeck, the Danish company said Monday. Charl van Zyl, head of ...

Depression continues to be an area of major medical need. A number of effective and well known antidepressants exist, including Prozac (Lilly) and Zoloft (Pfizer). These drugs, now available in ...

(Reuters) - Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of ...